Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

1 Sept 2016

Abstract excerpt

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting in the accumulation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27621679
DOI: 10.2147/jbm.s70716

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesPMID 27621679Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future PerspectivesSemantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Semantic proximity Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.